Characteristic | SLaM (n = 89) | BSMHFT (n = 22) | Total (n = 111) |
---|---|---|---|
Male gender (%) | 60 (67) | 19 (86) | 79 (71) |
Age at BEN registration (mean years ± SD) | 35 (11) | 34 (13) | 35 (12) |
Duration of illness (mean years ± SD) | 16.6 (5.6) | ND | ND |
Time to clozapine initiation from illness onset | |||
 (mean years ± SD) | 5.1 (4.5) | ND | ND |
 (median years, IQR) | 4.0 (7.0) | ND | ND |
Time to BEN identification from first clozapine initiation | |||
 (mean years ± SD) | 3.1 (4.3) | 0.7 (1.4)a | 2.7 (4.0) |
 (median years, IQR) | 1.2 (4.0) | 0.1 (0.7)a | 0.6 (3.3) |
Diagnosis (%) | |||
 F20 Paranoid Schizophrenia | 72 (82) | 22 (100) | 94 (84) |
 F25 Schizoaffective disorder | 12 (13) | 0 (0) | 12 (11) |
 F31 Bipolar disorder | 2 (2) | 0 (0) | 2 (2) |
 Other | 3 (3) | 0 (0) | 3 (3) |
Psychiatric co-morbidity (%) | 5 (6) | 0 (0) | 5 (5) |
Ethnicity (%) | |||
 White | 4 (4) | 1 (5) | 5 (5) |
 Black | 84 (95) | 16 (73) | 100 (90) |
 Asian | 0 (0) | 0 (0) | 0 (0) |
 Other | 1 (1) | 5 (22) | 6 (5) |
BEN Identification (%) | |||
 By a haematologist | 85 (96) | 18 (82) | 103 (93) |
 Monitored off-licence | 4 (4) | 4 (18) | 8 (7) |
Red results prior to BEN identification | |||
 n (%) | 28 (31) | 6 (27) | 34 (31) |
 (mean, SD) | 1 (2) | 1 (1) | 1 (2) |
 (median, IQR) | 0 (1) | 0 (1) | 0 (1) |
Amber results prior to BEN identification | |||
 n (%) | 56 (63) | 11 (50) | 67 (60) |
 (mean, SD) | 6 (10) | 6 (12) | 6 (10) |
 (median, IQR) | 2 (6) | 2 (6) | 2 (6) |